SCHEMBL5451795

SCHEMBL5451795

COc1ccccc1CNC(=O)c1cc2ccccc2n(-c2cccc(C(F)(F)F)c2)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.50
TP53 P04637 1/20 0.50
THRB P10828 1/20 0.50
RXFP1 Q9HBX9 1/20 0.49
PDE10A Q9Y233 1/20 0.48
HPGD P15428 3/20 0.48
ALDH1A1 P00352 4/20 0.48
TSHR P16473 3/20 0.48
HTT P42858 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MEN1 O00255 1/20 0.48
PLA2G10 O15496 1/20 0.48
NPC1 O15118 1/20 0.47
PKM P14618 1/20 0.46
ELANE P08246 1/20 0.46
KDM4E B2RXH2 2/20 0.45
RCE1 Q9Y256 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5442982 0.91 MAPT (0.47) TP53RXFP1HPGDTSHRHTT
SCHEMBL5434662 0.87 PLA2G10 (0.51) TP53LMNAPLA2G10ELANE
SCHEMBL5434616 0.86 PLA2G10 (0.48) PLA2G10ELANE
SCHEMBL5435540 0.86 PLA2G10 (0.50) TP53THRBALDH1A1HTTKMT2A
SCHEMBL5437758 0.86 TP53 (0.58) TP53THRBPDE10AHPGDKMT2A
SCHEMBL5434347 0.85 RECQL (0.56) TP53RXFP1KMT2ALMNAMAPT
SCHEMBL5757528 0.85 ELANE (0.63) GAATP53THRBRXFP1PDE10A
SCHEMBL5444631 0.85 TP53 (0.53) TP53RXFP1HPGDALDH1A1KMT2A
SCHEMBL5435722 0.85 PLA2G10 (0.43) HPGDALDH1A1TSHRKMT2ALMNA
SCHEMBL5434666 0.83 ELANE (0.55) HPGDALDH1A1HTTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010551-A1 Quinoline derivatives as neutrophil elastase inhibitors and their use ASTRAZENECA AB (SE) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010551-A1 Quinoline derivatives as neutrophil elastase inhibitors and their use SERPINB1, ELANE, MPO GAA 285/4885TP53 2493/4885THRB 3243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.